12 Dec 2023 • The recently unveiled 2024 Standards of Care offer updated and comprehensive guidance across various critical aspects of diabetes management.

Notable updates to the Standards of Care in Diabetes─2024 include:

• New updates in managing obesity in people with diabetes
• New screening recommendations for heart failure in people with diabetes.
• Updated recommendations for peripheral arterial disease (PAD) screening in people with diabetes.
• Guidance on screening and the use of teplizumab, approved to delay the onset of type 1 diabetes.
• More guidance on the use of new obesity medications, glucagon-like peptide 1 (GLP-1) agonists or dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, to reach sustained weight management goals.
• Updates in guidance on the diagnosis and classification of diabetes.
• A focus on hypoglycemia prevention and management.
• Emphasis on screening people with diabetes for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis at primary care and diabetes clinics.
• New emphasis on the evaluation and treatment of bone health and added attention to diabetes-specific risk factors for fracture.
• A focus on screening and management of people with diabetes and disability.
• Emphasis on enabling health care providers to master diabetes technology, using artificial intelligence for retinal screenings with necessary referrals, and embracing telehealth and digital tools for diabetes self-management education.
• New information on the possible association between COVID-19 infections and new onset of type 1 diabetes.

Source: ADA | Read full story